Stock Track | Bicycle Therapeutics Plunges 6% Following RBC Downgrade and Target Price Cut

Stock Track

Oct 31, 2025

Shares of Bicycle Therapeutics Limited (BCYC) plummeted 6.05% in pre-market trading on Friday, following a significant downgrade from RBC Capital Markets. The sharp decline comes as investors react to the change in analyst sentiment and a substantial reduction in the stock's target price.

RBC Capital Markets lowered its rating on Bicycle Therapeutics from Outperform to Sector Perform, signaling a less optimistic outlook for the company. Moreover, the financial institution drastically cut its target price for BCYC from $27 to $11, representing a 59% reduction. This substantial downward revision in the target price suggests that RBC analysts have reassessed their expectations for Bicycle Therapeutics' future performance, potentially due to concerns about the company's growth prospects or market position in the competitive healthcare sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1148629238"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148629238\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148629238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148629238","market":"hk","top_or_hot":-1,"title":"Stock Track | Bicycle Therapeutics Plunges 6% Following RBC Downgrade and Target Price Cut","media":"Stock Track","content":"<p>Shares of Bicycle Therapeutics Limited (BCYC) plummeted 6.05% in pre-market trading on Friday, following a significant downgrade from RBC Capital Markets. The sharp decline comes as investors react to the change in analyst sentiment and a substantial reduction in the stock's target price.</p>\n\n<p>RBC Capital Markets lowered its rating on Bicycle Therapeutics from Outperform to Sector Perform, signaling a less optimistic outlook for the company. Moreover, the financial institution drastically cut its target price for BCYC from $27 to $11, representing a 59% reduction. This substantial downward revision in the target price suggests that RBC analysts have reassessed their expectations for Bicycle Therapeutics' future performance, potentially due to concerns about the company's growth prospects or market position in the competitive healthcare sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bicycle Therapeutics Plunges 6% Following RBC Downgrade and Target Price Cut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bicycle Therapeutics Plunges 6% Following RBC Downgrade and Target Price Cut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bicycle Therapeutics Limited (BCYC) plummeted 6.05% in pre-market trading on Friday, following a significant downgrade from RBC Capital Markets. The sharp decline comes as investors react to the change in analyst sentiment and a substantial reduction in the stock's target price.</p>\n\n<p>RBC Capital Markets lowered its rating on Bicycle Therapeutics from Outperform to Sector Perform, signaling a less optimistic outlook for the company. Moreover, the financial institution drastically cut its target price for BCYC from $27 to $11, representing a 59% reduction. This substantial downward revision in the target price suggests that RBC analysts have reassessed their expectations for Bicycle Therapeutics' future performance, potentially due to concerns about the company's growth prospects or market position in the competitive healthcare sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCYC","symbol_name":"Bicycle Therapeutics Limited","start_time":0,"source_url":"","article_id":"1148629238","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148629238","pubTimestamp":1761917703,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bicycle Therapeutics Limited (BCYC) plummeted 6.05% in pre-market trading on Friday, following a significant downgrade from RBC Capital Markets. The sharp decline comes as investors react...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCYC":"Bicycle Therapeutics Limited"},"translate_title":"个股追踪|加拿大皇家银行下调评级和下调目标价后，Bicycle Therapeutics暴跌6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCYC":1},"content_text":"Shares of Bicycle Therapeutics Limited (BCYC) plummeted 6.05% in pre-market trading on Friday, following a significant downgrade from RBC Capital Markets. The sharp decline comes as investors react to the change in analyst sentiment and a substantial reduction in the stock's target price.\nRBC Capital Markets lowered its rating on Bicycle Therapeutics from Outperform to Sector Perform, signaling a less optimistic outlook for the company. Moreover, the financial institution drastically cut its target price for BCYC from $27 to $11, representing a 59% reduction. This substantial downward revision in the target price suggests that RBC analysts have reassessed their expectations for Bicycle Therapeutics' future performance, potentially due to concerns about the company's growth prospects or market position in the competitive healthcare sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}